Loading...
Latest News2023-07-31T14:16:37-04:00

Ella Korets-Smith of Virica Biotech Featured in Ottawa Business Journal for Advancing Gene Therapy

Our own Ella Korets-Smith, Chief Strategy Officer and co-founder of Virica Biotech, has been featured in the Ottawa Business Journal for her impactful role in advancing breakthrough biotechnology to “democratize gene therapy.” Virica’s vision is to make gene therapies accessible and affordable. Ella shares her entrepreneurial journey building Virica from an idea to a thriving business, expressing enthusiasm for Virica’s growing momentum. Virica’s Viral Sensitizer (VSETM) Technology “makes cells more friendly to viruses,” unlocking improved yield and productivity to achieve the scale these life-saving therapies need. With over 50 clients starting to use the products and scale their platforms, the [...]

January 24th, 2024|

Virica Expands Bioprocessing Capabilities with Carleton University Partnership

Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vectors and cell and gene therapies, announces a significant expansion of bioprocessing services through a strategic partnership with Carleton University in a PRESS RELEASE. "This multi-year, multi-million-dollar research and infrastructure partnership will help drive innovation and talent development in the Ottawa region for the creation and manufacturing of advanced therapies," said Rafik Goubran, Ph.D., Vice-President (Research and International) and Chancellor’s Professor, Carleton University. Slated to open this spring, Virica’s new facility at the university multiplies the company’s capacity to provide high throughput virology services for customers [...]

January 17th, 2024|

Cell & Gene Insights Fast Facts: Is Bigger Better in Viral Vector Manufacturing?

Cell & gene therapy (C&GT) is complex, expensive and lacks standardization. How do you effectively evaluate and make informed decisions to identify a winning viral vector production strategy to improve the accessibility & affordability of C&GT? We are thrilled to announce our Fast Facts video with Cell & Gene Insights, where our expert Andrea Vervoort, Technical Lead, breaks down key cost drivers of AAV manufacturing and the commercial impacts of incorporating Virica’s Viral Sanitizers (VSETM) using Biopharm’s BioSolve Bioprocess modelling. Click here to view our latest bioprocess modelling data in a Fast Facts video on Cell & Gene Insights!

January 11th, 2024|

Virica Kicks Off 2024 with a New Head of Global Sales and a Full Presentation Calendar

Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vectors, as well as cell and gene therapies, announced today the expansion of their sales team along with a full presentation calendar in a PRESS RELEASE.  Azra Benson, a veteran stem cell scientist with extensive commercial experience in the cell and gene therapy space, joins Virica as Head of Global Sales. It's exciting to have Azra join us at this pivotal time as we look forward to a busy 2024, working with clients to scale-up their life-changing cell and gene therapies. “An exciting first quarter lies [...]

January 5th, 2024|

Webinar Announcement: Closing the Gap of AAV Scale Up: Jan 25th 2024

Closing the gap: Modeling benefits of AAV scale-up using novel enhancers In partnership with Cell and Gene Insights, Virica will present on the benefits of viral sensitizers and show how bioprocessing modeling can be used to inform decisions related to scaling up or scaling out processes. Presenters will include; Dr. Jean-Simon Diallo (CEO Virica Biotech), Jondavid De Jong (VP, Scientific Operations), Anreao Vervoort (Technical Lead at Virica Biotech). Expect to gain a better understanding of: The impact of innate antiviral defenses on viral vector yield and quality An overview of the mode of action and benefits of VSEs A [...]

December 18th, 2023|

Antiviral Defenses: What You Need To Know

Innate cellular antiviral defences present a significant challenge to viral vector production and transduction for cell and gene therapy manufacturing. Learn about what they are, the challenges they pose and Virica's solution to mitigating its impact on viral vector yield and quality. View infographic here: Antiviral Defenses: What You Need to Know          

November 9th, 2023|

Virica’s Jean-Simon Diallo and JonDavid De Jong Featured in the Latest BioInsights Interview

In this interview Jean-Simon Diallo, CEO and Scientific Founder, and JonDavid De Jong, VP Scientific Operations discuss the challenges antiviral defenses pose to the successful production of vaccines and advanced therapies and what Virica is doing to tackle this problem. Check out the interview with BioInsights here! Read full interview:  Virica's BioInsights Interview

September 21st, 2023|

The Impact of Antiviral Defenses in Viral Vector Production

The impact of innate cellular antiviral defenses has emerged as a crucial area of investigation in viral vector manufacturing. Several recent publications have highlighted that the cell's natural response to the introduction of foreign genetic material can trigger defenses that hinder viral production efficiency. Although there have been any approaches to circumvent these barriers, the antiviral network's complexity is not an easy limitation to overcome. Learn more about the antiviral defenses present in current manufacturing  cell lines and strategies to mitigate their impact on viral vector production in this white paper, "The Impact of Antiviral Impact on Viral Vector Production."

July 18th, 2023|

Virica Joins Canadian Pandemic Preparedness Hub

Virica is pleased to announce it is part of the Canadian Pandemic Preparedness Hub (CP2H), a new research hub designed to protect Canadians against future pandemics and emerging threats. This multidisciplinary hub is part of an investment by the Government of Canada to grow a strong and competitive biomanufacturing and life sciences sector. “To continue to protect Canadians and to build a resilient biomanufacturing ecosystem, our government is taking every action possible to be equipped with the best tools. We’re proud to foster the research needed to produce cutting-edge discoveries and products in our very own labs that will help [...]

May 10th, 2023|

Archives

Categories

Breakthrough technology is both intimidating and exhilarating

Innovation is needed achieve the promise of advanced therapies and to make vaccines accessible to all. We’re here to help you realize this goal by providing our expertise and experience. We’re here to guide the way. Let’s Talk

Go to Top